Spiropyrrolidine derived antiviral agents

Inventors

Gao, Xuri • Li, Wei • Zhang, Jiajun • Peng, Xiaowen • Cao, Hui • Kass, Jorden • Shen, Ruichao • Wang, Guoqiang • Or, Yat Sun

Assignees

Enanta Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12643905-B2

Patent

Publication Date

2026-06-02

Expiration Date


Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Core Innovation

The disclosure describes compounds represented by Formula (I), or pharmaceutically acceptable salts thereof, featuring a peptidomimetic scaffold with a nitrile-containing fused bicyclic or spirocyclic core. Disclosed structural subfamilies encompass Formulae (I-A), (II)–(XIII), (XVI), (XVII), and (XXIV)–(XXVII), with defined variations for A, linker L1-L2, B, X, and substituents R1 through R16. These variants incorporate aryl, heteroaryl, cycloalkyl, alkyl, halo, cyano, and deuterated substituents alongside acyl or sulfonyl linkages.

The compounds inhibit coronavirus 3C-like protease, viral replication, and polyprotein processing for treating or preventing coronavirus infections, including SARS-CoV-2 and human coronavirus 229E. The disclosure provides screening results and structural characterization data, while underlying technical problem details remain omitted from the text. Documented teachings further encompass pharmaceutical compositions, combination therapy, and respiratory-disorder applications.

Claims Coverage

The provided claims identify one independent claim directed to compounds of Formula (I), alongside dependent claims covering compositions and methods, establishing three inventive features.

Formula (I) compounds and pharmaceutically acceptable salts

Independent claim 1 covers a compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, with defined alternatives for A (selected from —R11, —NR13R14, and —OR12), the L1-L2 linker, B, X, and substituents R1 through R16, including hydrogen, optionally substituted or deuterated alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl groups, or a heterocyclic ring formed by R13 and R14.

Pharmaceutical composition

A dependent claim covers a pharmaceutical composition comprising the claimed Formula (I) compound or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or excipient.

Treatment of coronavirus infection

Dependent claims cover a method of treating infection by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus by administering a therapeutically effective amount of the claimed compound or its pharmaceutically acceptable salt, with a further claim specifying a human subject.

The claim coverage centers on the Formula (I) compound genus and its pharmaceutically acceptable salts, with dependent claims providing coverage for pharmaceutical compositions and the treatment of specified coronavirus infections in human subjects.

Stated Advantages

The compounds inhibit coronavirus 3C-like protease (3CLpro/Mpro) and viral replication.

Documented Applications

Treatment or prevention of coronavirus infection, particularly SARS-CoV-2, as well as infections caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus, including treatment of a human subject.

Pharmaceutical compositions comprising a claimed compound or pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or excipient.

Respiratory-disorder applications.

Combination therapy.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.